Head-to-head · free

First Tracks Biotherapeutics Inc vs Twist Bioscience

TRAX vs TWST — return on capital, cash generation, margins and balance sheet side by side.

TRAX

1 / 2

measures where TRAX leads

TWST

1 / 2

measures where TWST leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTRAXTWST · FY2026
Revenue——
Net income—(130.2M)
Revenue growth (yearly, multi-year)——
Free cash flow—(89.0M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-40.9%-16.4%
Gross margin—50.7%
Operating margin—-36.2%
Net debt / EBITDA0.69x1.64x

Figures are as reported by each company; latest fiscal year shown.

Where First Tracks Biotherapeutics Inc's cash went

Not reported yet.

Full TRAX profile →

Where Twist Bioscience's cash went (FY2026)

Capital spending
$47.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TWST profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons